Eribulin
- Generic Name
- Eribulin
- Brand Names
- Halaven, Eribulin Baxter, Mevlyq
- Drug Type
- Small Molecule
- Chemical Formula
- C40H59NO11
- CAS Number
- 253128-41-5
- Unique Ingredient Identifier
- LR24G6354G
- Background
Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid ...
- Indication
For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.
- Associated Conditions
- Metastatic Liposarcoma, Refractory, metastatic Breast cancer, Unresectable Liposarcoma
- Associated Therapies
- -
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT00879086
- Locations
- 🇺🇸
Northwest Cancer Center, Corpus Christi, Texas, United States
🇺🇸Texas Oncology-Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Northern Utah Associates, Ogden, Utah, United States
Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2006-12-22
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT00415324
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸University of Southern California/Norris Cancer Center, Los Angeles, California, United States
🇺🇸University of California at Davis Cancer Center, Sacramento, California, United States
Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT00410553
- Locations
- 🇨🇦
Ottawa Hospital-Civic Campus, Ottawa, Ontario, Canada
🇨🇦University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-11-17
- Last Posted Date
- 2015-01-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 66
- Registration Number
- NCT00400829
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2017-10-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 15
- Registration Number
- NCT00383760
- Locations
- 🇨🇦
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2006-08-17
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 132
- Registration Number
- NCT00365157
- Locations
- 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸Decatur Memorial Hospital, Decatur, Illinois, United States
🇺🇸Community Howard Regional Health, Kokomo, Indiana, United States
E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
- Conditions
- Interventions
- First Posted Date
- 2006-06-15
- Last Posted Date
- 2020-06-18
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 1276
- Registration Number
- NCT00337103
- Locations
- 🇧🇪
Institut Jules Bordet, Medical Oncology Unit, Brussels, Belgium
🇦🇺Royal Perth Hospital, Perth, Western Australia, Australia
🇦🇺Bankstown Hospital, Oncology Trials Unit, Bankstown, New South Wales, Australia
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
- First Posted Date
- 2006-06-15
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT00337129
- Locations
- 🇺🇸
Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States
🇺🇸Kalispell Medical Oncology at KRMC, Kalispell, Montana, United States
🇺🇸UVMC Cancer Care Center at Upper Valley Medical Center, Troy, Ohio, United States
Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
- Conditions
- Interventions
- First Posted Date
- 2006-06-15
- Last Posted Date
- 2014-06-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 121
- Registration Number
- NCT00337077
- Locations
- 🇺🇸
Sparrow Hospital, Lansing, Michigan, United States
🇺🇸Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Virtua West Jersey Hospital Voorhees, Voorhees, New Jersey, United States
Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-06-08
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 74
- Registration Number
- NCT00334893
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.